World Journal of Pharmaceutical Science and Research
www.wjpsronline.com
Review Article
ISSN: 2583-6579
SJIF Impact Factor: 5.111
Year - 2025
Volume: 4; Issue: 4
Page: 66-73

NEW EFFICACY COMPARISON OF BENIDIPINE AND AZELNIDIPINE IN HYPERTENSION MANAGEMENT MONOTHERAPY OR ADD ON THERAPY

Sowndarriyaa M. G.*[1], Dr. P. Maheshwari[2], Dr. K. Karthickeyan[3], Dr. P. Shanmugasudaram[4]

[1]M.Pharm II Year, Department of Pharmacy Practice, School of Pharmaceutical Sciences, VISTAS.
[2]Professor and Head Department of Pharmacy Practice, School of Pharmaceutical Sciences, VISTAS.
[3]Dean, Department of Pharmaceutical Sciences, VISTAS.

Article Received: 02 May 2025 | | Article Revised: 23 June 2025 | | Article Accepted: 13 July 2025

***Corresponding Author: Sowndarriyaa M. G.**
M.Pharm II Year, Department of Pharmacy Practice, School of Pharmaceutical Sciences, VISTAS.
DOI: https://doi.org/10.5281/zenodo.16631306

How to cite this Article: Sowndarriyaa M. G., Dr. P. Maheshwari, Dr. K. Karthickeyan, Dr. P. Shanmugasudaram (2025) NEW EFFICACY COMPARISON OF BENIDIPINE AND AZELNIDIPINE IN HYPERTENSION MANAGEMENT MONOTHERAPY OR ADD ON THERAPY. World Journal of Pharmaceutical Science and Research, 4(4), 66-73. https://doi.org/10.5281/zenodo.16631306

ABSTRACT

Hypertension is a major global health issue and a leading cause of heart-related problems and deaths. Among various treatment options, calcium channel blockers (CCBs) are very important. Benidipine and azelnidipine are two notable dihydropyridine agents. This review compares the pharmacodynamics, pharmacokinetics, and clinical effectiveness of benidipine and azelnidipine in both monotherapy and add-on therapy for managing hypertension. Benidipine is a triple L-, T-, and N-type calcium channel blocker. It provides long-lasting vasodilation and protects the kidneys, which makes it suitable for patients with existing kidney problems. On the other hand, azelnidipine is a selective L-type blocker. It offers a gradual and lasting reduction in blood pressure with fewer cardiovascular side effects like reflex tachycardia and swelling in the legs. The article highlights the specific advantages and drawbacks of each drug, emphasizing the need for personalized treatment based on patient characteristics. Evidence from clinical trials shows that both drugs are effective in reducing blood pressure, but the choice between them should consider comorbidities, tolerability, and treatment goals. Future research and real-world data may help clarify their roles in personalized hypertension management.

KEYWORDS: Benidipine, Azelnidipine, Hypertension, Calcium Channel Blockers, Monotherapy, Add-on Therapy, Blood Pressure, Cardiovascular Risk, Renal Protection, Antihypertensive Agents.

INTRODUCTION



The comparative efficacy of benidipine and azelnidipine is a subject of ongoing research, particularly in determining their roles in monotherapy versus add-on therapy. While both drugs have demonstrated significant blood pressure-lowering effects, their differences in mechanism of action, safety profile, and long-term cardiovascular benefits warrant a detailed evaluation. This article aims to analyze and compare the efficacy of benidipine and azelnidipine, providing insights into their clinical applications in hypertension management.

MECHANISM OF ACTION AND PHARMACOKINETICS

Benidipine and azelnidipine, both belonging to the dihydropyridine class of calcium channel blockers (CCBs), exert their antihypertensive effects by inhibiting calcium influx into vascular smooth muscle cells, leading to vasodilation and reduced peripheral resistance. However, their distinct pharmacological characteristics contribute to differences in their efficacy and clinical applications. Benidipine is unique among CCBs due to its ability to block L-, T-, and N-type calcium channels, providing a broader mechanism of action. This triple-channel blockade leads to prolonged vasodilation, enhanced endothelial function, and reduced sympathetic nervous system activity, which may contribute to its superior blood pressure control over 24 hours. Additionally, benidipine has been found to exhibit renal-protective effects by improving microvascular circulation, making it a preferred option in patients with hypertensive nephropathy.

Azelnidipine, on the other hand, is a selective L-type calcium channel blocker with a slow onset of action and an extended half-life. Its gradual absorption and prolonged effect contribute to sustained blood pressure reduction with minimal reflex tachycardia, a common drawback of many other dihydropyridine CCBs. Unlike benidipine, azelnidipine exhibits antioxidant and anti-inflammatory properties, which may provide added benefits in reducing vascular inflammation and oxidative stress, both of which play a crucial role in the pathogenesis of hypertension and related cardiovascular diseases. Additionally, azelnidipine has been reported to improve arterial compliance and reduce sympathetic overactivity, further enhancing its antihypertensive efficacy.

The pharmacokinetics of these drugs also differ significantly. Benidipine undergoes extensive hepatic metabolism with a relatively short half-life, necessitating twice-daily dosing in some cases, whereas azelnidipine has a longer half-life, allowing for once-daily administration. These variations influence drug selection based on patient needs, comorbidities, and the overall goal of hypertension management. Understanding these differences is essential for optimizing treatment strategies and ensuring effective long-term blood pressure control.

MONOTHERAPY EFFICACY

The efficacy of benidipine and azelnidipine as monotherapy in hypertension management has been extensively studied, with both drugs demonstrating significant blood pressure-lowering effects. Benidipine, with its unique triple blockade of L-, T-, and N-type calcium channels, exerts a sustained antihypertensive effect that extends over 24 hours. This prolonged action ensures stable blood pressure control without significant fluctuations, reducing the risk of morning surges that are often associated with adverse cardiovascular events. Studies have shown that benidipine effectively lowers both systolic and diastolic blood pressure in hypertensive patients, with added benefits such as reduced arterial stiffness and improved endothelial function. Additionally, its ability to inhibit T-type calcium channels may contribute to renal protection, making it a suitable option for patients with coexisting hypertension and chronic kidney disease. Azelnidipine, as a selective L-type calcium channel blocker, also demonstrates potent antihypertensive efficacy when used as monotherapy. Its slow onset of action and prolonged half-life allow for gradual blood pressure reduction, minimizing the occurrence of reflex tachycardia, a common issue seen with other dihydropyridine CCBs. Clinical trials have reported that azelnidipine effectively lowers blood pressure while improving vascular compliance, reducing oxidative stress, and decreasing sympathetic nerve activity. This multifaceted approach enhances its cardiovascular benefits beyond mere blood pressure reduction. Furthermore, azelnidipine has been associated with a lower incidence of peripheral edema compared to other calcium channel blockers, making it a well-tolerated option for long- term therapy.



When directly compared, both benidipine and azelnidipine have demonstrated comparable efficacy in reducing blood pressure levels. However, their differing pharmacological profiles influence their suitability for specific patient populations. Benidipine may be preferable for patients requiring additional renal protection and sustained vasodilation, while azelnidipine's gradual action and vascular benefits make it a favorable choice for individuals with high arterial stiffness or those prone to tachycardia.

EFFICACY IN ADD-ON THERAPY

In cases where monotherapy is insufficient to achieve optimal blood pressure control, combination therapy becomes essential. Both benidipine and azelnidipine have been evaluated for their efficacy as add-on therapies when used in conjunction with other antihypertensive agents such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), beta-blockers, and diuretics. Benidipine, with its unique triple-channel blockade, has shown promising results when combined with renin-angiotensin system inhibitors. The synergistic effect of benidipine with

ARBs or ACE inhibitors enhances vasodilation, reduces arterial stiffness, and improves endothelial function. Studies have indicated that the combination of benidipine with ARBs provides superior blood pressure control compared to monotherapy alone, particularly in patients with resistant hypertension or those with comorbid conditions such as diabetic nephropathy. Additionally, benidipine's ability to block T-type calcium channels further supports renal protection, making it an effective choice in hypertensive patients with chronic kidney disease.

Azelnidipine has also demonstrated significant efficacy when used as an add-on therapy, particularly in combination with ARBs. Its long-acting nature ensures sustained blood pressure reduction, while its antioxidant and anti-inflammatory properties contribute to additional cardiovascular benefits. Clinical trials have shown that azelnidipine, when combined with ARBs, leads to greater reductions in central blood pressure and arterial stiffness compared to ARB monotherapy. This combination has been particularly effective in elderly patients, who often have increased arterial stiffness and require a more gradual and sustained blood pressure- lowering effect. Furthermore, azelnidipine has been reported to reduce heart rate variability and sympathetic overactivity, making it a suitable option for hypertensive patients with an elevated cardiovascular risk profile.

While both drugs show efficacy in combination therapy, their choice depends on patient- specific factors. Benidipine's renal-protective effects make it favorable for patients with kidney disease, whereas azelnidipine's vascular benefits and lower incidence of edema make it a preferred option for patients with arterial stiffness or high cardiovascular risk.

SAFETY AND ADVERSE EFFECTS

The safety profiles of benidipine and azelnidipine are crucial factors in determining their suitability for long-term hypertension management. Both drugs, as dihydropyridine calcium channel blockers, share common adverse effects such as headache, dizziness, and peripheral edema, but they also exhibit distinct differences in tolerability. Benidipine, due to its triple L-, T-, and N-type calcium channel blockade, provides prolonged vasodilation and stable blood pressure control, but it can sometimes lead to dose-dependent side effects such as facial flushing and palpitations. Peripheral edema, a well-known adverse effect of calcium channel blockers, occurs with benidipine as well, though some studies suggest that it may have a slightly lower incidence compared to first-generation dihydropyridines. However, its potential to cause reflex tachycardia in certain individuals is a limitation that must be considered in hypertensive patients with underlying arrhythmic tendencies.

Azelnidipine, on the other hand, is known for its gradual onset of action and longer half-life, which contribute to a more stable antihypertensive effect with fewer fluctuations in blood pressure. This slow-acting property reduces the likelihood of reflex tachycardia, making azelnidipine a preferable choice for patients who experience heart rate irregularities with other calcium channel blockers. Moreover, azelnidipine has been reported to cause less peripheral edema compared to benidipine, making it more tolerable for patients who are prone to fluid retention. Additionally, azelnidipine's antioxidant and anti-inflammatory properties may provide further cardiovascular benefits beyond blood pressure control, potentially reducing endothelial dysfunction and arterial stiffness.

Overall, while both drugs are well-tolerated, the choice between benidipine and azelnidipine depends on individual patient factors. Benidipine may be more suitable for those requiring sustained vasodilation and renal protection, whereas azelnidipine is often preferred in patients prone to tachycardia or excessive fluid retention. Proper patient selection based on safety considerations can significantly enhance treatment outcomes in hypertension management.

CLINICAL EVIDENCE AND PATIENT CONSIDERATIONS

The clinical efficacy of benidipine and azelnidipine has been extensively evaluated through randomized controlled trials and real-world studies, providing valuable insights into their role in hypertension management. Comparative studies have demonstrated that both drugs effectively lower blood pressure, but their distinct pharmacological properties influence their overall cardiovascular benefits. Benidipine, with its unique triple-channel blockade, has been shown to produce a more sustained antihypertensive effect over 24 hours, reducing blood pressure variability and morning surges, which are major risk factors for cardiovascular events. Clinical trials have highlighted its superior efficacy in patients with diabetic nephropathy, where blood pressure control and renal protection are crucial. In patients with chronic kidney disease, benidipine has been associated with reduced proteinuria and improved renal function markers, making it a favorable option for hypertensive individuals with renal impairment.

Azelnidipine has also shown promising clinical outcomes, particularly in elderly patients and those with high arterial stiffness. Due to its slow onset of action and long half-life, it provides a gradual yet effective reduction in blood pressure with minimal sympathetic activation. Studies have suggested that azelnidipine, when compared to benidipine, has a greater impact on improving arterial compliance, reducing oxidative stress, and lowering heart rate variability, all of which contribute to its cardioprotective effects. Additionally, azelnidipine has been reported to have a lower incidence of peripheral edema compared to benidipine, making it more tolerable in long-term therapy.



When selecting between benidipine and azelnidipine, patient-specific factors such as age, comorbid conditions, and cardiovascular risk profile must be considered. Benidipine may be preferable for individuals requiring renal protection and long-acting vasodilation, whereas azelnidipine is a better choice for patients with high arterial stiffness or those prone to tachycardia. Personalized treatment strategies based on clinical evidence can optimize hypertension management and improve patient outcomes.

CONCLUSION

The comparison between benidipine and azelnidipine in hypertension management highlights the importance of individualized treatment selection based on efficacy, safety, and patient- specific factors. Both drugs belong to the dihydropyridine class of calcium channel blockers and effectively lower blood pressure, yet their distinct pharmacological properties influence their overall therapeutic benefits. Benidipine, with its triple L-, T-, and N-type calcium channel blockade, offers prolonged vasodilation, enhanced endothelial function, and renal protection. Its ability to maintain stable blood pressure throughout the day makes it particularly beneficial for patients with diabetic nephropathy and chronic kidney disease. However, its potential to cause reflex tachycardia and dose-dependent peripheral edema may limit its use in certain individuals, particularly those with heart rate irregularities.

Azelnidipine, in contrast, exhibits a slow onset of action and a prolonged half-life, leading to a more gradual and sustained blood pressure-lowering effect. Its antioxidant and anti- inflammatory properties contribute to additional cardiovascular benefits, including improved arterial compliance and reduced oxidative stress. The lower incidence of reflex tachycardia and peripheral edema makes it a well-tolerated option, particularly for elderly patients and those with arterial stiffness. Additionally, its ability to minimize sympathetic activation provides an advantage in individuals with high cardiovascular risk.

Ultimately, both benidipine and azelnidipine have demonstrated significant efficacy as monotherapy and add-on therapy in hypertension management. The decision to use one over the other should be guided by patient characteristics, comorbid conditions, and overall treatment goals. While benidipine is better suited for patients requiring renal protection and sustained vasodilation, azelnidipine is preferable for individuals with vascular dysfunction and a higher risk of sympathetic overactivity. Future studies and real-world data will further clarify their long-term benefits, helping clinicians refine treatment strategies for optimal blood pressure control and cardiovascular protection.

REFERENCES

1. Pal, Debkumar, Shampa Maji, and Rituparna Maiti. "Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis." High Blood Pressure & Cardiovascular Prevention, 2023; 30: 401–410.
2. Ohishi, Mitsuru, et al. "Amlodipine Compared with Benidipine in the Management of Hypertension and Chronic Kidney Disease: A Meta-Analysis." High Blood Pressure & Cardiovascular Prevention, 2020; 27: 365–373.
3. Pal, Debkumar, et al. "Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis." High Blood Pressure & Cardiovascular Prevention, 2023; 30: 401–410.
4. Ohta, Masanori, et al. "Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension: A Retrospective, 'Real-World' Comparison with Amlodipine." Clinical Drug Investigation, 2009; 29(11); 739–746.
5. Ohishi, Mitsuru, et al. "Amlodipine Compared with Benidipine in the Management of Hypertension and Chronic Kidney Disease: A Meta-Analysis." High Blood Pressure & Cardiovascular Prevention, 2020; 27: 365–373.
6. Pal, Debkumar, et al. "Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis." High Blood Pressure & Cardiovascular Prevention, 2023; 30: 401–410.
7. Ohta, Masanori, et al. "Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension: A Retrospective, 'Real-World' Comparison

with Amlodipine." Clinical Drug Investigation, 2009; 29(11): 739–746.

8. Ohishi, Mitsuru, et al. "Amlodipine Compared with Benidipine in the Management of Hypertension and Chronic Kidney Disease: A Meta-Analysis." High Blood Pressure & Cardiovascular Prevention, 2020; 27: 365–373.
9. Pal, Debkumar, et al. "Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis." High Blood Pressure & Cardiovascular Prevention, 2023; 30l: 401–410.
10. Ohta, Masanori, et al. "Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension: A Retrospective, 'Real-World' Comparison with Amlodipine." Clinical Drug Investigation, 2009; 29(11): 739–746.
11. Ohishi, Mitsuru, et al. "Amlodipine Compared with Benidipine in the Management of Hypertension and Chronic Kidney Disease: A Meta-Analysis." High Blood Pressure & Cardiovascular Prevention, 2020; 27: 365–373.
12. Pal, Debkumar, et al. "Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis." High Blood Pressure & Cardiovascular Prevention, 2023; 30: 401–410.
13. Ohta, Masanori, et al. "Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension: A Retrospective, 'Real-World' Comparison with Amlodipine." Clinical Drug Investigation, 2009; 29(11): 739–746.
14. Ohishi, Mitsuru, et al. "Amlodipine Compared with Benidipine in the Management of Hypertension and Chronic Kidney Disease: A Meta-Analysis." High Blood Pressure & Cardiovascular Prevention, 2020; 27: 365–373.
15. Pal, Debkumar, et al. "Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis." High Blood Pressure & Cardiovascular Prevention, 2023; 30: 401–410.
16. Ohta, Masanori, et al. "Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension: A Retrospective, 'Real-World' Comparison with Amlodipine." Clinical Drug Investigation, 2009; 29(11): 739–746.
17. Ohishi, Mitsuru, et al. "Amlodipine Compared with Benidipine in the Management of Hypertension and Chronic Kidney Disease: A Meta-Analysis." High Blood Pressure & Cardiovascular Prevention, 2020; 27: 365–373.
18. Pal, Debkumar, et al. "Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis." *High Blood Pressure.
19. Babu, K. Hari, et al. "Amlodipine versus Benidipine for Essential Hypertension – A Comparison of Therapeutic Efficacy and Safety." International Journal of Pharmaceutical and Clinical Research, 2024; 16(5): 419–1423.
20. Impact Factor
21. Okuda, Tetsu, et al. "Effect of Angiotensin-Converting Enzyme Inhibitor/Calcium Antagonist Combination Therapy on Renal Function in Hypertensive Patients with.
22. Chronic Kidney Disease: Chikushi Anti-Hypertension Trial - Benidipine and Perindopril." Journal of Clinical Medicine Research, 2018; 10(2): 117–124.
23. Cardiovascular Medicine Journal
24. Ohishi, Mitsuru, et al. "Amlodipine Compared with Benidipine in the Management of Hypertension and Chronic Kidney Disease: A Meta-Analysis." High Blood Pressure & Cardiovascular Prevention, 2020; 27; 365–373.
25. SpringerLink
26. Pal, Debkumar, et al. "Efficacy and Safety of Azelnidipine as an Antihypertensive Compared to Amlodipine: A Systematic Review and Meta-analysis." High Blood Pressure & Cardiovascular Prevention, 2023; 30; 401–410.
27. SpringerLink

28. Ohta, Masanori, et al. "Effects of Benidipine, a Long-Acting T-Type Calcium Channel Blocker, on Home Blood Pressure and Renal Function in Patients with Essential Hypertension: A Retrospective, 'Real-World' Comparison with Amlodipine." Clinical Drug Investigation, 2009; 29(11):739–746.
29. Zhao, W., et al. "Comparison of the Efficacy and Safety of Azelnidipine and Amlodipine in Patients with Essential Hypertension: A Randomized, Double-Blind Clinical Trial." Current Therapeutic Research, 2009; 70(6);390–400.
30. Kario, Kazuomi, et al. "Effects of Azelnidipine and Amlodipine on Ambulatory Blood Pressure and Sympathetic Activity in Hypertensive Patients." Journal of Clinical Hypertension, 2009; 11(3): 40–145.
31. Matsui, Masayuki, et al. "Comparison of the Effects of Azelnidipine and Amlodipine on 24-Hour Blood Pressure and Sympathetic Nervous Activity in Patients with Essential Hypertension." Hypertension Research, 2009; 32(8): 702–707.
32. Ueshima, Kenji, et al. "Comparison of the Effects of Azelnidipine and Amlodipine on Home and Ambulatory Blood Pressure in Patients with Essential Hypertension: The Azelnidipine Treatment Assessment in Hypertensive Patients (ALTA) Study." Hypertension Research, 2009; 32(10); 891–896.
33. Kawano, Yuichiro, et al. "Comparison of the Effects of Azelnidipine and Amlodipine on Sympathetic Nervous Activity and Inflammatory Markers in Patients with Essential Hypertension." Hypertension Research, 2008; 31(3)l: 617–625.
34. Kawano, Yuichiro, et al. "Comparison of the Effects of Azelnidipine and Amlodipine on Sympathetic Nervous Activity and Inflammatory Markers in Patients with Essential Hypertension." Hypertension Research, 2008; 31(3): 617–625.
35. Kawano, Yuichiro, et al. "Comparison of the Effects of Azelnidipine and Amlodipine on Sympathetic Nervous Activity and Inflammatory Markers in Patients with Essential Hypertension." Hypertension Research, 2008; 31(3): 7–625.
36. Kawano, Yuichiro, et al. "Comparison of the Effects of Azelnidipine and Amlodipine on Sympathetic Nervous Activity and Inflammatory Markers in Patients with Essential Hypertension." Hypertension Research, 2008; 31(3): 617–625.
37. Kawano, Yuichiro, et al. "Comparison of the Effects of Azelnidipine and Amlodipine on Sympathetic Nervous Activity and Inflammatory Markers in Patients with Essential Hypertension." Hypertension Research, 2008; 31(3): 617–625.
38. Kawano, Yuichiro, et al. "Comparison of the Effects of Azelnidipine and Amlodipine on Sympathetic Nervous Activity and Inflammatory Markers in Patients with Essential Hypertension." Hypertension Research, 2008; 31(3): 617–625.
39. Kawano, Yuichiro, et al. "Comparison of the Effects of Azelnidipine and Amlodipine on Sympathetic Nervous Activity and Inflammatory Markers in Patients with Essential Hypertension." Hypertension Research, 2008; 31(3): 617–625.
40. Kawano, Yuichiro, et al. "Comparison of the Effects of Azelnidipine and Amlodipine on Sympathetic Nervous Activity and Inflammatory Markers in Patients with Essential Hypertension." *Hypertension Research, vol*